Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Assets (2016 - 2025)

Adma Biologics (ADMA) has disclosed Assets for 14 consecutive years, with $624.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets rose 27.74% year-over-year to $624.2 million, compared with a TTM value of $624.2 million through Dec 2025, up 27.74%, and an annual FY2025 reading of $624.2 million, up 27.74% over the prior year.
  • Assets was $624.2 million for Q4 2025 at Adma Biologics, up from $568.7 million in the prior quarter.
  • Across five years, Assets topped out at $624.2 million in Q4 2025 and bottomed at $232.8 million in Q2 2021.
  • Average Assets over 5 years is $373.4 million, with a median of $345.7 million recorded in 2022.
  • The sharpest move saw Assets fell 5.53% in 2023, then soared 48.45% in 2024.
  • Year by year, Assets stood at $276.3 million in 2021, then rose by 26.14% to $348.5 million in 2022, then dropped by 5.53% to $329.2 million in 2023, then soared by 48.45% to $488.7 million in 2024, then increased by 27.74% to $624.2 million in 2025.
  • Business Quant data shows Assets for ADMA at $624.2 million in Q4 2025, $568.7 million in Q3 2025, and $558.4 million in Q2 2025.